A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response-Reference-Cited by-同舟云学术

A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Published:2014-08-28 Issue:5 Volume:96 Page:599-608
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Nguyen T H T,Mentré F,Levi M,Yu J,Guedj J

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference49 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. Emerging treatments for hepatitis C

3. Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era

4. Profile of alisporivir and its potential in the treatment of hepatitis C

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy of antiviral strategies targeting different stages of the viral life cycle: A viral quasispecies dynamics study;2022-10-11

2. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C;Acta Pharmacologica Sinica;2017-09-07

3. Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification;Pharmaceutical Research;2017-06-28

4. Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga;Journal of Infectious Diseases;2016-08-10

5. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8+ T cell activation;Journal of Hepatology;2016-06